Given higher pass-throughs, what is the new expected EBITDA margin range, and how are back-half loaded cost actions tracking?

Nigel stated that at the midpoint of guidance, full-year EBITDA margin would be ~16.5%, but higher pass-throughs could lower it to the low 16% range. Cost actions are built into the anticipated H2 EBITDA progression. “If it were the case that pass-throughs ran faster through the balance of the year, and let's say, we ended up at the higher end of the range, well, again, mathematically, if you're at the top end of the revenue range, but the midpoint of the EPS range, if that's where we landed, that would lower that 16.5% down to something closer to the low 16%.”

How sustainable is the Q2 SG&A performance, and what will drive gross margin improvement in H2 given mix dynamics?

Nigel indicated that Q1 SG&A is a better run rate for H2 as Q2 benefited from non-recurring items. H2 margin progression will be driven by gross margin expansion due to improving mix effects and cost actions, rather than SG&A. “I would think our Q1 SG&A number is a better run rate to think about for the rest of the year rather than the Q2. So the implication of that, of course, being where do we see the margin progression as we go through the balance of the year will be more on the gross margin line as we see the benefits of that mix effect, as we talked about and as well as obviously, the cost actions that we have taken.”

How should we think about burn rates from backlog given the composition of strong bookings, including Phase III trials and FSO vs FSP mix?

Barry highlighted increased Phase III opportunities in RFP flow (50% vs 40% a year ago) and continued FSO outperformance in book-to-bill. He noted cardiometabolic research is growing, especially in biotech, alongside oncology, and that the burn rate is mathematically suppressed by strong book-to-bills. “The burn rate itself is naturally just mathematically suppressed a little bit by the strong book-to-bills we've been posting, but I'm concerned with the underlying burn rate, how effectively are we burning those studies that are running such that we're generating revenue and then obviously, very, very careful management of our costs to ensure we do that incrementally more profitably than previously.”

ICLR

ICON (ICLR) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Industrials· Jul 30, 2026

Source: earnings call transcript

Executive summary

ICON Q2 FY26 — Strong Bookings and AI Collaboration

ICON delivered solid Q2 FY26 results, marked by robust bookings and a constructive demand environment, despite elevated pass-through activity impacting reported margins. The company reaffirmed its full-year financial guidance, focusing on sequential EBITDA dollar progression and disciplined cost management. Strategic investments in AI, including a new collaboration with Anthropic, and expansion in China are aimed at strengthening its competitive position and driving long-term growth.

Highlights

Net book-to-bill ratio of 1.51x in Q2 FY26, driven by $3.1 billion in net bookings.
Gross business wins increased 24% year-over-year and 13% sequentially to $3.7 billion.
RFP flow increased 22% sequentially and 16% on a trailing 12-month basis.
Phase III opportunities represented approximately 50% of total opportunity volume in Q2 FY26, up from 40% a year ago.
Strong free cash flow of $238.9 million in Q2 FY26, reducing net debt to $2.5 billion.

Concerns

Elevated pass-through activity impacted reported adjusted EBITDA margin, which was 15.9% in Q2 FY26 compared to 20.5% in Q2 FY25.
Adjusted SG&A expense in Q2 FY26 benefited from non-recurring items, not expected to recur in the second half of the year.
Underlying direct fee revenue is expected to decline organically by approximately 2% year-over-year for FY26, as per guidance.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Financial Guidance	Reaffirmed high materiality	FY26	High
Full-year 2026 Adjusted Effective Tax Rate	Approximately 17% medium materiality	FY26	High
EBITDA Dollar Progression	Sequential improvement high materiality	H2 FY26	High
Share Repurchases	Plans for Q3 and H2 medium materiality	Q3 · FY26	High
Underlying Direct Fee Revenue Growth	Approximately -2% high materiality	FY26	High

ICLR operating KPIs by quarter

ICLR operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Mar 2026 Q1 FY26	This call Jun 2026 Q2 FY26	Change vs prior quarter
Gross bookings	$3.3B Quarter 1 gross bookings were $3.3 billion, matching the strong performance in quarter 4 2025 and up 22% year-over-year. Source: earnings call transcript	$3.7B Q2 gross business wins were $3.7 billion, an increase of 24% year-over-year and 13% sequentially with strong performance across the portfolio. Source: earnings call transcript	+12.1%
Cancellations	$383M Cancellations were also in line with the improved level seen in quarter 4, a total of $383 million for the quarter. Source: earnings call transcript	$562M Cancellations totaled $562 million, broadly in line with expectations, resulting in net bookings of $3.1 billion and a net book-to-bill ratio of 1.51x. Source: earnings call transcript	+46.7%
Net business wins	$2.88B Strength of gross bookings and cancels resulted in net business wins of $2.88 billion in the quarter, an increase of 42% year-over-year and a net book-to-bill of 1.42x. Source: earnings call transcript	$3.1B Cancellations totaled $562 million, broadly in line with expectations, resulting in net bookings of $3.1 billion and a net book-to-bill ratio of 1.51x. Source: earnings call transcript	+7.6%
Net book-to-bill	1.42 x Strength of gross bookings and cancels resulted in net business wins of $2.88 billion in the quarter, an increase of 42% year-over-year and a net book-to-bill of 1.42x. Source: earnings call transcript	1.51 x Cancellations totaled $562 million, broadly in line with expectations, resulting in net bookings of $3.1 billion and a net book-to-bill ratio of 1.51x. Source: earnings call transcript	+6.3%
Book-to-bill Direct fee	1.3 x+ Encouragingly, we again saw a solid contribution of direct fee versus pass-through awards with our book-to-bill on a direct fee basis in excess of 1.3x for the quarter. Source: earnings call transcript	1.2 x Direct fee bookings also remained strong, resulting in a direct fee net book-to-bill ratio of 1.2x. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

Product	Type	Timeline	Details
Specialty biomarker testing and pathology	expansion	—

Deals & partnerships

Anthropic Multiyear collaboration to advance domain expertise through targeted investments in architecture and frontier models, enhancing AI capabilities for clinical trials. Multiyear

Collaboration represents an important milestone for ICON's AI strategy, strengthening the technology architecture underpinning its clinical trial delivery platform.

Microsoft Collaboration to strengthen the technology architecture underpinning ICON's clinical trial delivery platform.

Partnership focuses on creating data lakes, unified ontology, and mastering data to drive insights from structured data using frontier AI models, forming the foundation of ICON's AI infrastructure.

Leading Chinese biotech company New partnership supporting global development programs, including full-service capabilities, laboratories, and imaging.

This partnership rewards ICON's investments in China and reflects its ability to partner with Chinese companies going global, requiring a global partner for drug development.

Symphony Divestment of Symphony business.

The divestiture occurred in the middle of Q2 FY26.

Risks & headwinds

Elevated pass-through activity impacting reported margins H2 FY26

Adjusted EBITDA margin of 15.9% in Q2 FY26 compared to 20.5% in Q2 FY25; potential for pass-through levels to exceed prior assumption of flat year-over-year.

Mitigation:Focus on delivering EBITDA dollars and driving sequential improvement in both EBITDA dollars and margin in the second half.

SG&A expense benefit from non-recurring items in Q2 H2 FY26

Q2 SG&A was lower than expected due to timing of certain items.

Mitigation:These items are not expected to recur in H2; margin progression in H2 will be driven more by gross margin expansion and cost actions.

Higher proportion of ballpark proposals in biotech Q2 FY26

Reversion to historical win rates in biotech as ICON engages with certain customers for the first time.

Mitigation:Continuing to grow footprint, early bidding, and thoughtful strategy to see more of the biotech market.

Underlying direct fee revenue decline organically FY26

Approximately 2% year-over-year decline for FY26, implied by guidance.

Mitigation:Cost actions and improving mix effect in H2 are expected to drive gross margin expansion.

Inflation in clinical trial costs Ongoing

Not explicitly quantified, but driven by healthcare inflation, particularly in the U.S., and increased cost of procedures (e.g., MRI).

Mitigation:Not explicitly stated, but implies focus on efficiency, value generation, and ability to run complex trials.

What to watch in Q3 FY26

Share Repurchase Execution

Q3 FY26 and H2 FY26

Current Commitment to return capital, plans for Q3 and H2.

Target Execution of share repurchases.

Why it matters

Demonstrates commitment to capital allocation and shareholder returns, impacting EPS.

It remains our intention to get back in the markets as we had outlined previously... we certainly have some plans for Q3 and the back half of the year in general.

Find out whether ICLR delivers this. Inve re-checks your case every morning.

Q&A highlights

How is the demand environment progressing across customer cohorts (large pharma, biotech), and how might heavier pass-throughs impact revenue guidance?

Barry clarified that biotech demand accelerated, while large pharma RFP flow moderated but remained healthy. Nigel explained that higher pass-throughs could push revenue to the higher end of the range, but margin percentage would be impacted, with management focused on EBITDA dollars.

“It is possible that if pass-throughs continue to run stronger that, yes, that would impact obviously, where we would land within that revenue range and with a consequent impact likewise on the margin evolution as we go through the year.”

asked by David Windley · answered by Nigel Clerkin

3 min read 5 chapters

Detailed narrative

AI Strategy and Partnerships

ICON's AI strategy emphasizes domain expertise and targeted investments in architecture and frontier models, rather than generic applications. The multiyear collaboration with Anthropic, alongside its existing partnership with Microsoft, aims to strengthen the technology architecture underpinning its clinical trial delivery platform.

This strategy focuses on enhancing the intelligence layer for Orbis (ICON's Agentic AI platform), improving productivity, and developing domain-specific agents like MRIdian for clinical monitoring workflows. These initiatives are designed to streamline study design, accelerate protocol development, enhance patient and site engagement, and reduce administrative burdens, ultimately creating value for customers and strengthening ICON's competitive position.

Demand Environment and Bookings Performance

The demand environment remains constructive, with Q2 FY26 gross business wins reaching $3.7 billion, a 24% year-over-year and 13% sequential increase. Net bookings were $3.1 billion, resulting in a net book-to-bill ratio of 1.51x. Awards were broad-based across customer groups, with improved win rates in large pharma and significant FSP program additions.

Biotech RFP flow saw a marked increase, aligning with ICON's strategic objective to expand in this market, though it included a higher proportion of ballpark proposals. Phase III opportunities now represent approximately 50% of total opportunity volume, up from 40% a year ago, indicating a shift towards later-stage development assets.

Pass-Through Activity and Margin Impact

Elevated pass-through activity continued to benefit reported revenue and net bookings in Q2 FY26 but had a dampening effect on reported margins. The adjusted EBITDA margin for the quarter was 15.9%, compared to 20.5% in Q2 FY25. This trend is expected to persist in the second half of the year due to therapeutic mix and site location dynamics.

Management's focus remains on delivering absolute EBITDA dollars and achieving sequential improvement in both EBITDA dollars and margin in H2, acknowledging that the actual reported margin percentage will depend on the pass-through mix.

China Expansion and Market Opportunity

ICON is expanding its capabilities in China, including a significant laboratory expansion to add specialty biomarker testing and pathology, building on prior investments in Singapore. This commitment to strengthening its Asia Pacific lab footprint was underscored by a new partnership with a leading Chinese biotech company for global development programs, encompassing full-service capabilities, laboratories, and imaging.

While China remains a relatively modest portion of total revenues, revenue in China is projected to increase by as much as 20% in FY26 over FY25, reflecting growing opportunities with Western companies, Chinese companies running global trials, and Chinese companies seeking global partners.

Capital Allocation and Financial Position

The company's strong cash generation in Q2 FY26, with free cash flow of $238.9 million, further strengthened its financial position. Net debt decreased to $2.5 billion as of June 30, 2026, down from $2.6 billion in Q1 FY26 and $3 billion in Q2 FY25, resulting in a leverage ratio of 1.8x net debt to adjusted trailing 12-month EBITDA.

ICON remains committed to a balanced capital allocation framework, prioritizing investments in the business, pursuing strategic growth opportunities, and returning capital to shareholders through share repurchases, with plans to re-enter the market in Q3 and the second half of the year.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.